Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inotiv ( (NOTV) ) has provided an announcement.
On September 25, 2025, Inotiv, Inc. agreed to settle a securities class action and two derivative actions to avoid prolonged litigation costs and uncertainties. The settlements, pending court approval, involve a cash payment of $8.75 million funded by insurance and corporate governance changes. Additionally, Inotiv is addressing the impact of a 2025 cybersecurity incident affecting its operations and exploring debt refinancing options with Perella Weinberg Partners.
The most recent analyst rating on (NOTV) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Inotiv stock, see the NOTV Stock Forecast page.
Spark’s Take on NOTV Stock
According to Spark, TipRanks’ AI Analyst, NOTV is a Neutral.
Inotiv’s overall stock score is primarily impacted by its financial performance, which is under pressure due to high leverage and negative profitability. Technical analysis indicates a bearish trend, and valuation metrics are weak with a negative P/E ratio. The earnings call provided some positive insights with revenue growth and improved EBITDA, but challenges remain with net losses and cash flow issues. The cybersecurity incident adds further uncertainty to the company’s operational stability.
To see Spark’s full report on NOTV stock, click here.
More about Inotiv
Inotiv, Inc. operates in the industry of life sciences and provides contract research services, focusing on drug discovery and development services. The company is known for its comprehensive range of services that support pharmaceutical and biotechnology companies in their research and development efforts.
Average Trading Volume: 436,646
Technical Sentiment Signal: Sell
Current Market Cap: $48.78M
Learn more about NOTV stock on TipRanks’ Stock Analysis page.